Avalo Therapeutics Expands Pipeline with Next-Gen Anti-IL-1β Antibody AVTX-010
AVTX has more than doubled off its 52-week low of $4.46.
Summary
Avalo Therapeutics is expanding its pipeline with AVTX-010, a next-generation anti-IL-1β antibody, leveraging recent clinical success and financing to target hidradenitis suppurativa and other inflammatory disorders.
Key Events · Product Development and Regulatory · AVTX
-
Pipeline Expansion with AVTX-010
Avalo announced the advancement of AVTX-010, a long-acting next-generation anti-IL-1β monoclonal antibody, with potential for development in hidradenitis suppurativa (HS) and other inflammatory disorders.
-
IND Submission Planned for 2027
The company expects to submit an Investigational New Drug (IND) application for AVTX-010 in the first half of 2027, marking an early-stage development milestone.
-
Strategic Development Leveraging Recent Success
This pipeline expansion builds on the positive Phase 2 LOTUS trial data for abdakibart (AVTX-009) and the transformational financing completed in May, demonstrating a strategic focus on the IL-1β pathway.
Analysis · AVTX · Life Sciences
Avalo Therapeutics announced the advancement of AVTX-010, a long-acting next-generation anti-IL-1β monoclonal antibody, into its pipeline. This strategic move builds on the recent positive Phase 2 results for abdakibart in hidradenitis suppurativa and the company's strong financial position, aiming to develop a potentially best-in-class treatment with extended dosing intervals. An Investigational New Drug (IND) application is planned for the first half of 2027.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 29.9% of the 1678 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.25%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AVTX was trading at $14.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $767.5M. The 52-week trading range was $4.46 to $24.27. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.